tirzepatide surpass trials versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial SURMOUNT-1 Trial - Cardionerds Twitter

Endocr J 62:971980 Degn KB, Juhl CB, Sturis J et al (2004) One weeks treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes

Most primary care physicians in Pennsylvania are familiar with both Zepbound and Mounjaro and can evaluate your eligibility during a standard office visit

GLP-1 medications may not be appropriate for all patients

The lawsuit, filed in the United States District Court for the Western District of Texas, alleges that the defendants used their dominant market positions to undermine the compounding pharmacy industry, an established and essential component of the U.S

Likely effect on addiction Hjelmesth finds it plausible that GLP-1 medications could also have an independent effect on addiction to alcohol and potentially other substances